adenovirus vaccine
Recently Published Documents


TOTAL DOCUMENTS

122
(FIVE YEARS 29)

H-INDEX

25
(FIVE YEARS 3)

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1486
Author(s):  
Po-Wei Liao ◽  
Chieh-Lin Jerry Teng ◽  
Cheng-Wei Chou

We present a case of immune thrombocytopenia (ITP) induced by the chimpanzee adenovirus-vectored vaccine, without evidence of thrombosis, eight days after vaccine administration. The thrombocytopenia condition improved after administering steroid treatment. This adenovirus vaccine had been reported to induce rare side effects, such as immune thrombotic thrombocytopenia. This case report showed that it could also induce immune thrombocytopenia without the presence of thrombosis. Therefore, we should be cautious of this rare side effect as global vaccine administrations against coronavirus disease increase.


Vaccine ◽  
2021 ◽  
Author(s):  
Nai-Hsiang Chung ◽  
Ying-Chin Chen ◽  
Shiu-Ju Yang ◽  
Yu-Ching Lin ◽  
Horng-Yunn Dou ◽  
...  

Author(s):  
Hanna H. Pitkänen ◽  
Annukka Jouppila ◽  
Tuukka Helin ◽  
Vinaya Dulipati ◽  
Juha Kotimaa ◽  
...  
Keyword(s):  

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1221
Author(s):  
Coralie F. Daussy ◽  
Noémie Pied ◽  
Harald Wodrich

Adenovirus vector-based genetic vaccines have emerged as a powerful strategy against the SARS-CoV-2 health crisis. This success is not unexpected because adenoviruses combine many desirable features of a genetic vaccine. They are highly immunogenic and have a low and well characterized pathogenic profile paired with technological approachability. Ongoing efforts to improve adenovirus-vaccine vectors include the use of rare serotypes and non-human adenoviruses. In this review, we focus on the viral capsid and how the choice of genotypes influences the uptake and subsequent subcellular sorting. We describe how understanding capsid properties, such as stability during the entry process, can change the fate of the entering particles and how this translates into differences in immunity outcomes. We discuss in detail how mutating the membrane lytic capsid protein VI affects species C viruses’ post-entry sorting and briefly discuss if such approaches could have a wider implication in vaccine and/or vector development.


Author(s):  
Stefania Capone ◽  
Angelo Raggioli ◽  
Michela Gentile ◽  
Simone Battella ◽  
Armin Lahm ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 299 ◽  
Author(s):  
Olivia Flynn ◽  
Kate Dillane ◽  
Juliane Sousa Lanza ◽  
Jennifer M. Marshall ◽  
Jing Jin ◽  
...  

Adenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing immunity. Here we determined how dissolvable microneedle patches (DMN) for skin immunization can overcome this issue, using a clinically-relevant adenovirus-based Plasmodium falciparum malaria vaccine, AdHu5–PfRH5, in mice. Incorporation of vaccine into patches significantly enhanced its thermostability compared to the liquid form. Conventional high dose repeated immunization by the intramuscular (IM) route induced low antigen-specific IgG titres and high anti-vector immunity. A low priming dose of vaccine, by the IM route, but more so using DMN patches, induced the most efficacious immune responses, assessed by parasite growth inhibitory activity (GIA) assays. Administration of low dose AdHu5–PfRH5 using patches to the skin, boosted by high dose IM, induced the highest antigen-specific serum IgG response after boosting, the greatest skewing of the antibody response towards the antigen and away from the vector, and the highest efficacy. This study therefore demonstrates that repeated use of the same adenovirus vaccine can be highly immunogenic towards the transgene if a low dose is used to prime the response. It also provides a method of stabilizing adenovirus vaccine, in easy-to-administer dissolvable microneedle patches, permitting storage and distribution out of cold chain.


2021 ◽  
Author(s):  
Olivia Flynn ◽  
Kate Dillane ◽  
Juliane Sousa Lanza ◽  
Jennifer M. Marshall ◽  
Jing Jin ◽  
...  

ABSTRACTAdenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases including COVID-19. However the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralising immunity. Here we determined how dissolvable microneedle patches (DMN) for skin immunization can overcome this issue, using a clinically-relevant adenovirus-based Plasmodium falciparum malaria vaccine, AdHu5-PfRH5, in mice. Incorporation of vaccine into patches significantly enhanced its thermostability compared to the liquid form. Conventional high dose repeated immunization by the intramuscular (IM) route induced low antigen-specific IgG titres and high anti-vector immunity. A low priming dose of vaccine, by the IM route but more so using DMN patches, induced the most efficacious immune responses, assessed by parasite growth inhibitory activity (GIA) assays. Administration of low dose AdHu5-PfRH5 using patches to the skin, boosted by high dose IM, induced the highest antigen-specific serum IgG response after boosting, the greatest skewing of the antibody response towards the antigen and away from the vector and the highest efficacy. This study therefore demonstrates that repeated use of the same adenovirus vaccine can be highly immunogenic towards the transgene if a low dose is used to prime the response. It also provides a method of stabilising adenovirus vaccine, in easy-to-administer dissolvable microneedle patches, permitting storage and distribution out of cold chain.


2020 ◽  
Vol 140 (12) ◽  
pp. 2528-2531.e2 ◽  
Author(s):  
Geza Erdos ◽  
Stephen C. Balmert ◽  
Cara Donahue Carey ◽  
Gabriel D. Falo ◽  
Nikita A. Patel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document